Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients

Kerstin Clasen1 · Stefan Welz1,2 · Heidrun Faltin3 · Daniel Zips1,2 · Franziska Eckert1,2,3

Received: 3 July 2021 / Accepted: 19 September 2021 / Published online: 20 October 2021
© The Author(s) 2021

Abstract

Purpose High Mobility Group Box 1 (HMGB1) protein has been described as a consensus marker for immunogenic cell death (ICD) in cancer. To personalize treatments, there is a need for biomarkers to adapt dose prescription, concomitant chemotherapy, and follow-up in radiation oncology. Thus, we investigated the levels of HMGB1 in plasma of patients with head and neck squamous cell carcinoma (HNSCC) during the course of radiochemotherapy and follow-up in correlation with oncologic outcome and clinical confounders.

Methods In our pilot study, 11 patients with advanced HNSCC were treated with definitive radiochemotherapy. Blood samples were taken weekly during treatment and frequently at follow-up visits. HMGB1 levels as well as routine laboratory values were measured and clinical information was collected including tumor volume, infections, toxicity, and follow-up data.

Results In total, 85 samples were analyzed. In eight patients, HMGB1 levels (baseline vs. last available sample during treatment) were increasing and in three patients HMGB1 values were decreasing toward the end of treatment. All three patients with decreasing values developed tumor recurrence. By contrast, no relapse occurred in patients that showed increasing HMGB1 levels during therapy. Moreover, a positive correlation of HMGB1 levels with tumor volumes, C-reactive protein (CRP) levels, infections, and grade three toxicity (RTOG) was observed.

Conclusion HMGB1 might be a promising marker to monitor ICD in HNSCC during the course of radiochemotherapy. However, HMGB1 seems to reflect complex and diverse immunogenic responses and potential confounders. Infections and treatment-associated toxicity should be considered when interpreting the dynamics of HMGB1.

Keywords Immunogenic cell death · Head and neck cancer · Plasma · Biomarker · Radiotherapy

Availability of data and material The data can be shared on request.

Code availability Not applicable

Franziska Eckert, MD
franziska.eckert@med.uni-tuebingen.de

1 Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076Tuebingen, Germany

2 German Cancer Research Center (DKFZ) partner site Tuebingen, German Cancer Consortium (DKTK), Hoppe-Seyler-Straße 3, 72076 Tuebingen, Germany

3 Section for Experimental Radiation Oncology, Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076Tuebingen, Germany

Introduction

For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), definitive radiochemotherapy is a standard treatment. However, in spite of intense treatment, tumor recurrence remains an issue since locoregional control rates of only approximately 60% after 2 years are reported [1]. Therefore, there is a need for personalized therapeutic approaches and the identification of biomarkers to individualize therapy (de-)escalation during the course of radiotherapy [2–4]. For this purpose, blood-based biomarkers seem promising as they are easy to obtain and repeatedly achievable during treatment. Recently, increasing attention has been paid to immune-related markers to monitor cancer treatment and response.

High Mobility Group Box 1 (HMGB1) protein has been described to act as both a chromatin associated, non-histone transcription factor in the nucleus [5, 6] as well as
a mediator of immune response if released to the extracellular space [7–9]. The latter might be of clinical use as a biomarker since increased serum levels of HMGB1 were found in a “late” mediator of immune response 8 h after endotoxin stimulation in a murine model and were proven to be elevated in patients with sepsis [7]. HMGB1 specifically stimulates tumor necrosis factor (TNF) synthesis in monocytes as well as the synthesis of diverse further proinflammatory cytokines as downstream cascades of immune response [10]. HMGB1 has been investigated as a biomarker for tumor outcome and therapy response in tumor tissue as well as in blood plasma or serum samples [11]. High HMGB1 expression was described as a negative prognostic factor in a meta-analysis of clinical studies [12]. In glioblastoma, recurrent tumors showed lower HMGB1 expression compared to the respective primary tumors [13]. However, the biology of intracellular HMGB1 in the tumor (as detected by immunohistochemistry in the tumor tissue) is different from the role of extracellular HMGB1, which mainly serves as a danger signal for the immune system. HMGB1 concentration in blood serum might rather be associated with this function of the protein and it has been described to be associated with prognosis in several cancer entities [14–16] and might serve as a biomarker in oncolytic virotherapy [17].

In cancer treatment, tumor-specific immune responses can be triggered by radiation [18] and by certain chemotherapeutics [19] as well as other forms of oncologic treatment such as locoregional hyperthermia [20, 21]. One mechanism described is immunogenic cell death (ICD), characterized by the release of danger signals (damage-associated molecular patterns, DAMPs) stimulating innate immune responses. HMGB1 has been described as one of the key players in ICD signaling in anticancer treatment [8] and as a consensus marker to monitor ICD in serum samples [22]. Of the markers of immunogenic cell death described in the Consensus guideline in 2015 [22], only HMGB1 can be measured in blood serum and plasma, as adenosine triphosphate (ATP) acts in the tumor microenvironment and calreticulin is exposed on tumor cells. In the updated guideline [23], other danger molecules have been added as possible ICD markers measurable in serum and plasma, such as the heat shock proteins (HSP) Hsp70 [24, 25] and Hsp90 [26]. In addition, correlation of serum markers with cellular immunomonitoring during radio(chemo)therapy [27, 28] might lead to further insights into systemic immune changes induced by cancer treatments.

However, besides being involved in ICD in cancer, HMGB1 also mediates diverse responses to inflammatory and infectious diseases [29, 30] such as, for example, pancreatitis and sepsis [31], pneumonia [32], stroke [33], or vasculitis [34]. This consideration might be important when monitoring ICD by HMGB1 during cancer therapy if inflammation and/or infection accompany the treatment.

Our intent in this study was to monitor HMGB1 during the course of radiochemotherapy in HNSCC patients and to correlate the dynamics with clinical features and outcome parameters.

**Material and methods**

This prospective pilot biomarker study included 11 patients with newly diagnosed, locally advanced HNSCC. All patients provided written informed consent and the study was approved by the local ethics committee (reference number 064/2016BO2).

After exclusion of distant metastases, all patients were treated by intensity-modulated radiotherapy (IMRT) up to 70 Gy and concomitant chemotherapy with cisplatin weekly (n=8) or 5-flourouracil and mitomycin C (n=3). Laboratory values, clinical features such as the gross tumor volume (GTV) of the primary tumors and the lymph nodes, as well as treatment-associated toxicity according to the Radiation Therapy Oncology Group (RTOG) grading were recorded. Furthermore, we recorded infections during therapy (defined by clinically manifest symptoms plus either antibiotic treatment or positive microbiological findings).

To monitor the dynamics of immune markers in the plasma, blood was taken before therapy on day 1 (n=10) or on day 2 (n=1) for baseline assessment and weekly thereafter. Routine blood samples were taken at the same time, e.g., to monitor blood count and C-reactive protein (CRP) levels. To reduce potentially treatment-associated confounders, we took the weekly blood samples on Mondays (after the weekend) before irradiation or chemotherapy onset. “End of treatment” values are defined as the last available values during radiochemotherapy (range: day 28–46; mean: day 36 of treatment). If available, further samples and clinical data were collected during follow-up (3–6 monthly).

The blood collected in EDTA tubes (Sarstedt, Nümbrecht, Germany) was centrifuged twice for 10 min for plasma isolation and the plasma samples were stored at −80°C. Samples were thawed immediately before use for HMGB1 analysis. All time points of individual patients were measured in one assay.

All available plasma samples were analyzed by enzyme-linked immunosorbent assays (ELISAs) to measure levels of HMGB1. The measurements were performed according to the manufacturer’s instructions (IBL International GmbH, Hamburg, Germany, Reference Number ST51011). This ELISA kit is specifically designed to measure HMGB1 in human serum and plasma in addition to cell culture medium. Standard curves were measured in-
cluding HMGB1 concentrations of 0.625 ng/ml, 1.25 ng/ml, 2.5 ng/ml, 5.0 ng/ml, 10.0 ng/ml, 20.0 ng/ml, 40.0 ng/ml, and 80.0 ng/ml. The value of $R^2$ for the fit of the standard curves was 0.99. Every sample was tested in technical duplicates. Means were used for analysis. For eight samples (9.4%), the duplicates showed limited reproducibility. However, for further analysis, all time points were used because all values were in a plausible range.

**Statistical analysis**

Statistical analysis was performed with IBM SPSS Version 26 and GraphPad Version 8. Means were compared by the Mann–Whitney test if values did not pass the normality test, otherwise they were compared with Student’s $t$ test. Bonferroni correction was applied in the case of multiple testing. Survival times were estimated with the Kaplan–Meier method and compared by log-rank-test. Correlations of continuous variables are described using Pearson correlation coefficients ($r$; moderate correlation defined as 0.4–0.7; strong correlation defined as $>0.7$).

**Results**

Eight men and three women were included in this study and all completed definitive radiochemotherapy. The patients’ characteristics are shown in Table 1. In total, 85 samples were collected (of these 61 during radiochemotherapy and 24 during follow-up). Overall, 11 planned samples during radiochemotherapy could not be collected or analyzed (e.g., because of acute infection or anemia of the patients or technical difficulties). Five samples were taken either after radiation or on Tuesdays before radiation treatment.

| Gender       | $n$ | %   |
|--------------|-----|-----|
| Female       | 3   | 27% |
| Male         | 8   | 73% |

| Localization | $n$ | %   |
|--------------|-----|-----|
| Oropharynx   | 4   | 36% |
| Oropharynx/hypopharynx | 1 | 9% |
| Hypopharynx  | 5   | 46% |
| Larynx       | 1   | 9%  |

| Human papillomavirus (HPV) status | $n$ | %   |
|----------------------------------|-----|-----|
| Positive                         | 5   | 46% |
| Negative                         | 3   | 27% |
| Unknown                          | 3   | 27% |

| Involved lymph nodes | $n$ | %   |
|----------------------|-----|-----|
| Yes                  | 10  | 91% |
| No                   | 1   | 9%  |

The follow-up ranged from 940 to 1476 days (mean = 1345). All but one patient received frequent clinical examinations and imaging for follow-up. This patient did not show up for further follow-up after 136 days but confirmed subjective well-being in a telephone interview after 1475 days. Nevertheless, for recurrence analysis, the short follow-up (136 days) was used.

In the consecutive sampling, HMGB1 showed undulating values during treatment (Fig. 1a). Relative HMGB1 concentrations normalized to the start of treatment individually and follow-up values are shown in Fig. 1b. We compared the baseline value with end of treatment for each patient. In eight of 11 patients, the values were increasing toward the end of therapy (Fig. 1c). None of these patients showed tumor recurrence during follow-up. In three patients, HMGB1 levels in the last sample during radiochemotherapy were lower than the respective baseline. In all three patients with decreasing HMGB1, follow-up revealed tumor recurrence (Fig. 2; $p = 0.001$). Solitary lung metastases were treated (and histologically proven) by resection in two patients. One patient developed local recurrence and multiple metastases during follow-up. Comparing initial HMGB1 levels with change during therapy revealed a moderate negative correlation ($r = -0.46$; data not shown). Compared to the baseline values, the samples analyzed during follow-up showed lower levels of HMGB1 in all patients analyzed ($n = 10$; one patient did not show up for follow-up sampling) at all times (Fig. 1d).

Since HMGB1 was found to be elevated in inflammatory and infectious diseases as well, we recorded corresponding CRP levels ($n = 61$) and data on infections ($n = 53$) and treatment-associated toxicity ($n = 58$) during therapy. HMGB1 levels were compared with inflammation and infection in a pooled analysis of all available data for all patients during treatment. HMGB1 showed a moderate positive correlation with CRP levels (Fig. 3; $r = 0.45$ for both, relative and absolute HMGB1 levels). Furthermore, time points with relevant radiation toxicity (grade 3 according to RTOG) showed significantly higher relative HMGB1 levels compared to time points without toxicity using a Bonferroni-corrected Mann–Whitney test (Fig. 4a, $p = 0.017$). Five samples were taken when a clinically manifest infection occurred at the same time. At time points with infections, mean HMGB1 levels were also significantly higher than in samples taken without simultaneous infections (Fig. 4b, $p = 0.002$). The CRP levels were not significantly higher at time points with manifest infections ($3.5 ± 0.7$ mg/dl vs. $2.6 ± 0.3$ mg/dl, $p = 0.37$). Whereas there was no difference in CRP levels with grade 1 and grade 2 toxicity (data not shown), grade 3 toxicity was associated with significantly higher CRP levels compared to time points without toxicity ($4.7 ± 0.8$ mg/dl vs. $1.6 ± 0.3$ mg/dl, $p < 0.001$).
High Mobility Group Box 1 (HMGB1) concentrations were measured during radiochemotherapy (RT) as well as during follow-up (FU). While there were no consistent changes during treatment (a), HMGB1 levels decreased during follow-up in all patients (b). Comparing HMGB1 concentrations at baseline versus the last available samples during treatment, in eight patients concentrations increased, while three patients showed decreasing HMGB1 levels, indicated in gray (c). However, all HMGB1 concentrations at last follow-up were lower than initial levels (d). Cyan lines indicate means and standard errors for all patients.

Fig. 2 Three patients developed tumor recurrence during follow-up. Whereas there were no clinical features significantly influencing progression-free survival (data not shown), decreasing HMGB1 levels (end of treatment compared to baseline) significantly correlated with worse disease-free survival.

HMGB1 levels at time point 1 (baseline) were strongly correlated with the initial GTV (tumor+involved lymph nodes; $r=0.82$) contoured for radiotherapy planning, as shown in Fig. 5a. After exclusion of the patient with the largest tumor volume, HMGB1 at baseline was moderately correlated with the GTV ($r=0.48$). When analyzing the dynamics of HMGB1 levels during treatment (ratio of the last available sample to baseline), a moderate negative correlation with the GTV was observed (Fig. 5b).

Discussion

HMGB1 was described to be a consensus marker for ICD [22]. Compared to healthy donors, HMGB1 levels seem to be elevated in the serum of HNSCC patients [35]. However, data on monitoring HMGB1 in patients during the course of curative radio(chemo)therapy are rare. In a report of four patients receiving definitive radiochemotherapy for HNSCC and 13 patients treated in an adjuvant intention, elevated HMGB1 levels were described during follow-up in cases of recurrence. However, the authors in-
The inflammation marker C-reactive protein (CRP) was correlated with the respective HMGB1 levels in a pooled analysis of all available time points during treatment. Both absolute HMGB1 concentrations (a) as well as relative HMGB1 levels normalized to baseline (b) showed a moderate correlation with CRP concentrations.

HMGB1 levels at all time points were normalized to the baseline value of the respective patient and correlated with Radiation Therapy Oncology Group (RTOG)-graded treatment toxicity as well as apparent infections. While patients with very mild toxicity showed a slight but significant decrease in HMGB1 levels, grade 3 toxicity was associated with a significant HMGB1 increase compared to time points at which patients did not show any treatment toxicity (a). Although infections were only present at five time points in four patients, they were associated with significantly higher relative HMGB1 concentrations compared to time points without apparent infections (b).

Contoured volumes retrieved from the radiotherapy plans (gross tumor volume [GTV] of the primary tumor and involved lymph nodes) were correlated with HMGB1 concentrations. GTV volumes showed a strong positive correlation with initial HMGB1 levels (a). Change in HMGB1 concentrations during treatment (ratio of the last available HMGB1 concentrations during treatment to baseline) showed moderate negative correlations with the GTV volume (b).
response, probably indicating better anti-tumor immune responses possibly related to better tumor control.

Interestingly, in our cohort, two of the three patients with tumor relapse suffered from distant metastases while the tumor was locally controlled. One could speculate that in these patients the radiation dose was sufficient for local control but distant lesions occurred due to impaired systemic immune response associated with reduced ICD compared to the patients with rising HMGB1 levels during treatment.

Although our pilot results need to be confirmed in larger studies, the initial findings are very promising in regard to monitoring ICD and tumor response during treatment. If our results can be confirmed in the future, personalized treatment adaptations like (de)escalation could be discussed or follow-up intervals might be adapted and/or the addition of immunotherapeutic options according to immune status might be discussed.

However, especially in treatments with severe side effects and treatment-associated toxicities, confounders need to be considered when attributing rising HMGB1 levels to ICD in tumors. Radiochemotherapy in HNSCC causes dermatitis and mucositis as expected side effects. Furthermore, patients are immunocompromised due to concomitant chemotherapy and are prone to infections such as, for example, pneumonia or inflamed feeding tubes. In our cohort, manifest infections were rare (five time points). Thus, in spite of the significant correlation of infections and elevated HMGB1 levels, this sample size is too small for strong conclusions. However, in the literature [31, 32] the role of HMGB1 in inflammatory and infectious diseases was described before in different settings. Therefore, we believe, infections and high-grade toxicity should be reported and considered as potential confounders. HMGB1 levels at these time points might not reflect solely ICD and should be interpreted cautiously.

Furthermore, we found an association of elevated HMGB1 levels with rising CRP levels and with RTOG grade 3 toxicity. This is reasonable, as a positive correlation between CRP levels and HMGB1 was described before (in the setting of autoimmunity and inflammation; [31, 34]). As toxicity and inflammation are commonly elevated toward the end of treatment, it is hard to discriminate these confounders from ICD if rising HMGB1 levels are detected during therapy. This finding needs to be critically addressed and monitored if HMGB1 is used as a biomarker of ICD and linked to tumor response in future studies. Thus, we suggest special attention is given to treatment-associated confounders if severe side effects are expected such as toxicity ≥3 (RTOG grading) or whenever a patient has significantly rising CRP levels and manifest infections. Perhaps HMGB1 is an even more promising marker in particular types of cancer where no extensive toxicity is to be expected during radiotherapy.

The baseline levels of HMGB1 showed a positive correlation with the initial tumor volume, and during follow-up, all HMGB1 levels were lower than the respective baseline values. As only one patient had a significant tumor load at recurrence, we consider these findings promising. HMGB1 might reflect tumor necrosis pretherapeutically and it potentially qualifies as a follow-up marker.

**Conclusion**

In our longitudinal pilot study, High Mobility Group Box 1 protein (HMGB1) was found to be a promising biomarker to monitor tumor response in definitive radiochemotherapy for head and neck squamous cell carcinoma. However, besides outcome data, correlations with inflammation, toxicity, and infection could also be seen. Therefore, potential confounders must be considered when monitoring and interpreting HMGB1 levels during cancer treatment.

**Funding** This work was supported by the “Wilhelm Schuler-Stiftung” in Tuebingen, Germany (material expenses). Besides, K. Clasen was supported by the intramural Fortüne/PATE Program of the Medical Faculty, Eberhard Karls University of Tuebingen under Grant 2447-0-0. F. Eckert was partly supported by the Stiftung für KinderKrebshilfe (GKKF) and by the Deutsche Krebshilfe under grant 70114187.

**Author Contribution** All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Kerstin Clasen, Heidrun Faltin and Franziska Eckert. The first draft of the manuscript was written by Kerstin Clasen and Franziska Eckert and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** K. Clasen, S. Welz, D. Zips and F. Eckert have research and educational grants from Elekta, Philips, Siemens, Sennewald. H. Faltin declares that she has no competing interests.

**Ethical standards** This study was approved by the local ethics committee (reference number 064/2016BO2). All patients declared their (written) informed consent and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.o/.

References

1. Linge A et al (2016) HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German cancer consortium radiation oncology group (DKTK-ROG). Radiother Oncol 121(3):364–373
2. Baumann M et al (2016) Radiation oncology in the era of precision medicine. Nat Rev Cancer 16(4):234–249
3. Clasen K et al (2020) PET/MRI and genetic intrapatient heterogeneity in head and neck cancers. Strahlenther Onkol 196(6):542–551
4. Zwirner K et al (2019) Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. Strahlenther Onkol 195(9):771–779
5. Stros M et al (2002) HMGB1 and HMGB2 cell-symmetrically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 277(9):7157–7164
6. Bianchi ME, Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15(5):496–506
7. Wang H et al (1999) HM-1 as a late mediator of endotoxin lethality in mice. Science 285(5425):248–251
8. Apetoh L et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059
9. Liao Y et al (2020) HMGB1 in radiotherapy: a two headed signal regulating tumor radiosensitivity and immunity. Onco Targets Ther 13:6859–6871
10. Andersson U et al (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192(4):565–570
11. Vaes RDW et al (2021) Biomarkers of radiotherapy-induced immunogenic cell death. Cells 10(4):930
12. Wu T et al (2016) HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget 7(31):50417–50427
13. Muth C et al (2016) Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin. Strahlenther Onkol 192(3):146–155
14. Chung HW et al (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7:38
15. Chung HW et al (2012) Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 103(9):1714–1721
16. Qiu G et al (2014) Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 31(12):316
17. Liikanen I et al (2015) Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncol Immunology 4(3):e989771
18. Galluzzi L, Kepp O, Kroemer G (2013) Immunogenic cell death in radiation therapy. OncolImmunology 2(10):e26536
19. Tesniere A et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482–491
20. Adkins I et al (2014) Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. OncoImmunology 3(12):e968434
21. Schildkof P et al (2010) Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells. Biochem Biophys Res Commun 391(1):1014–1020
22. Kepp O et al (2014) Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 3(9):e955691
23. Galluzzi L et al (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 8(1):e337. https://doi.org/10.1136/jitc-2019-000337
24. Gehrmann M et al (2014) Hsp70—a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Radiat Oncol 9:131
25. Schmid TE, Multhoff G (2012) Radiation-induced stress proteins—the role of heat shock proteins (HSP) in anti-tumor responses. Curr Med Chem 19(12):1765–1770
26. Yan H et al (2017) Clinical significance of serum dynamics of HSP90α level in esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Cancer Biomark 19(2):185–192
27. Eckert F et al (2018) Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. OncoImmunology 7(1):e1496881
28. Hoffmann E et al (2021) Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03002-6
29. Yang H, Tracey KJ (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799(1–2):149–156
30. Klune JR et al (2008) HMGB1: endogenous danger signaling. Mol Med 14(7–8):476–484
31. Kocsis AK et al (2009) Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology 9(4):383–391
32. Angus DC et al (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35(4):1061–1067
33. Sapojnikova N et al (2014) Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. Biochim Biophys Acta 1842(9):1379–1384
34. Wang C et al (2013) Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res (Hoboken) 65(11):1828–1834
35. Wild CA et al (2012) HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48(3):409–416
36. Mytilinaios D et al (2020) Peripheral cytokine levels differ by HPV status and change treatment-dependently in patients with head and neck squamous cell carcinoma. Int J Mol Sci 21(17):5990. https://doi.org/10.3390/ijms21175990
37. Suzuki Y et al (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72(16):3967–3976